Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial-Reference-Cited by-同舟云学术

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Published:2021-02 Issue: Volume:103 Page:62-71
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Udwadia Zarir F.,Singh Pawan,Barkate Hanmant,Patil Saiprasad^ORCID,Rangwala Shabbir^ORCID,Pendse Amol^ORCID,Kadam Jatin^ORCID,Wu Wen,Caracta Cynthia F.^ORCID,Tandon Monika

Funder

lenmark Pharmaceuticals Limited, India

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference29 articles.

1. Favipiravir: a new and emerging antiviral option in COVID-19;Agrawal;Med J Armed Forces India,2020

2. Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients. Press Release. September 23, 2020. https://www.fujifilm.com/jp/en/news/hq/5451.

3. Duration of Isolation and Precautions for Adults with COVID-19. July 22, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html [Accessed 30 July 2020].

4. SARS-CoV-2 RNA polymerase as target for antiviral therapy;Buonaguro;J Transl Med,2020

5. Experimental treatment with favipiravir for COVID-19: an open-label control study;Cai;Engineering (Beijing),2020

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans;Heliyon;2024-08

2. A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5’-triphosphate (T-705-RTP) in human peripheral mononuclear cells;Journal of Pharmaceutical and Biomedical Analysis;2024-08

3. Challenges of consolidating evidence collected during a pandemic and lessons for the future;Current Medical Research and Opinion;2024-07-23

4. Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST);Journal of Infection and Public Health;2024-07

5. Hospitalization Endpoint in Clinical Trials of Outpatient Settings: using Anti-SARS-COV-2 Therapy as an Example;Clinical Epidemiology;2024-05